Encoded's ETX101 Cuts Dravet Seizures 76% at Dose Level 3 and Tracks Toward Neurotypical Development in Children Treated Before Age 2
An AAV9 gene-regulation therapy delivered durable, dose-dependent seizure control and early signs of neurodevelopmental rescue through 52 weeks, just as the pivotal study begins dosing.